Published in
American Association for the Advancement of Science, Science Translational Medicine, 579(13), 2021
DOI: 10.1126/scitranslmed.abb6282
Links
Tools
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate
Journal article published in 2021 by
Fan-En Kong 
,
Guang-Meng Li ,
Yun-Qiang Tang ,
Shao-Yan Xi,
Jane Ho Chun Loong ,
Mei Li,
Hao-Long Li ,
Wei Cheng ,
Wen-Jie Zhu,
Jia-Qiang Mo,
Yuan-Feng Gong ,
Hui Tang,
Yue Zhao,
Yan Zhang,
Stephanie Ma
and other authors.
,
Guang-Meng Li ,
Yun-Qiang Tang ,
Shao-Yan Xi,
Jane Ho Chun Loong ,
Mei Li,
Hao-Long Li ,
Wei Cheng ,
Wen-Jie Zhu,
Jia-Qiang Mo,
Yuan-Feng Gong ,
Hui Tang,
Yue Zhao,
Yan Zhang,
Stephanie Ma
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
CLDN6 is not only a marker of hepatocellular carcinoma but also a therapeutic target by promoting sorafenib resistance and lineage plasticity.